Sangart's Series G Adds $50M Now, $50M Later for MP4 Drugs
April 20, 2011
San Diego-based Sangart Inc. brought in more than $50 million in new equity funding to boost work on its MP4 pegylated hemoglobin platform in hemorrhage and sickle cell disease.
